Stock Events

Stock Events

Surrozen

$25.88

0

+$0+0% Friday 00:08

Statistics

Day High

25.88

Day Low

25.88

52W High

-

52W Low

-

Volume

600

Avg. Volume

-

Mkt Cap

221.82M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

13MayExpected

Q3 2025

Q4 2025

Next

-19.13

-13.1

-7.08

-1.05

Expected EPS

-1.0525

Actual EPS

N/A

Financials

-596.56%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

21.31MRevenue

-127.13MNet Income

Analyst Ratings

$38.00Average Price Target

The highest estimate is 40.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRZN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotech company that develops treatments for serious medical conditions, competing with Surrozen in the biopharmaceutical space, particularly in areas like regenerative medicine and tissue repair.

Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on creating new possibilities in medicine, including regenerative treatment options, which puts them in direct competition with Surrozen's efforts in tissue regeneration and repair.

Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Surrozen in the broader biopharmaceutical market.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is at the forefront of RNAi therapeutics, competing with Surrozen in the innovative treatment market, including potential overlaps in target diseases or conditions.

CRISPR Therapeutics

CRISPR Therapeutics is focused on developing gene-based medicines, which could compete with Surrozen's approach to using Wnt signaling for tissue repair and regeneration.

Novartis is a global healthcare company that operates in various therapeutic areas, including those that could overlap with Surrozen's focus on regenerative medicine and tissue repair.

Pfizer is a global biopharmaceutical company with a broad range of therapeutic products, some of which may compete with Surrozen's treatments in regenerative medicine and tissue repair.

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that develops innovative medicines, potentially competing with Surrozen in areas like liver disease treatment, where regenerative medicine is key.

About

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Show more...

CEO

ISIN

US86889P2083

Listings

0 Comments

Share your thoughts

FAQ

What is Surrozen stock price today?▼

The current price of SRZN.BOATS is $25.88 USD — it has increased by +0% in the past 24 hours. Watch Surrozen stock price performance more closely on the chart.

What is Surrozen stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Surrozen stocks are traded under the ticker SRZN.BOATS.

What is Surrozen market cap?▼

Today Surrozen has the market capitalization of 221.82M

When is the next Surrozen earnings date?▼

Surrozen is going to release the next earnings report on May 13, 2026.

What were Surrozen earnings last quarter?▼

SRZN.BOATS earnings for the last quarter are -19.13 USD per share, whereas the estimation was -1.29 USD resulting in a -1,385.83% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Surrozen revenue for the last year?▼

Surrozen revenue for the last year amounts to 21.31M USD.

What is Surrozen net income for the last year?▼

SRZN.BOATS net income for the last year is -127.13M USD.

When did Surrozen complete a stock split?▼

Surrozen has not had any recent stock splits.